Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Johnson and Johnson
Merck
Colorcon
Boehringer Ingelheim

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,298,804

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,298,804
Title:Variant database
Abstract: The invention provides a system and method for describing polymorphisms or genetic variants based on information about mutations and relationships among them. The invention uses object-oriented concepts to describe variants as variant objects and relations among those variants as variant relation object, each object being an instance of an abstract class of genomic feature and able to contain any number of other objects. Information about genetic disorders is stored in association with the object that represents the pathogenic variant. Genetic test results are used to access corresponding objects to provide a report based on variants or polymorphisms in a patient\'s genetic material.
Inventor(s): Nizzari; Marcia M. (Needham, MA), Breton; Benjamin H. (Woburn, MA), Tefft; David L. (Malden, MA), Haurie; Xavier S. (Belmont, MA)
Assignee: Good Start Genetics, Inc. (Cambridge, MA)
Application Number:14/329,243
Patent Claims:1. A method of describing mutations in a patient genome, the method comprising using a computer system comprising a memory coupled to a processor for: receiving data representing a first mutation and a second mutation in the patient genome; creating a first instance of an abstract class of genomic feature and storing in the first instance a number representing a start position in a reference human genome and at least one IUPAC character representing a nucleotide found in the patient genome at the start position and not found in the reference human genome; creating a second instance of the abstract class and storing in the second instance a second number representing a second start position, different from the first start position, in the reference human genome and at least one second IUPAC character representing a nucleotide found in the patient genome at the second start position and not found in the reference human genome; creating a third instance of the abstract class and storing in the third instance; the first instance, the second instance, and a description of a relationship between the first instance and the second instance; and describing the mutations in the patient genome based on the third instance.

2. The method of claim 1, further comprising: receiving data identifying a genomic region; and creating a fourth instance of the abstract class, the fourth instance comprising a description of a relationship between the genomic region and the first mutation and the second mutation.

3. The method of claim 2, wherein the genomic region is identified as one selected from the list consisting of: exon, intron, gene, and ORF.

4. The method of claim 2, wherein the genomic region is identified as one selected from the list consisting of: regulatory region, promoter, splice site, and non-coding region.

5. The method of claim 2, wherein the genomic region is identified as one selected from the list consisting of: epigenetically modified region and methylated sequence.

6. The method of claim 2, wherein the genomic region is identified as one selected from the list consisting of: protein motif and protein secondary structure.

7. The method of claim 1, wherein the first mutation is not already stored within the computer system.

8. The method of claim 7, further comprising storing the first instance in one or more computer storage devices.

9. A system for providing a description of a variant in a patient's genome, the system comprising: a processor; and a computer-readable storage device containing instructions which when executed by the processor cause the system to receive data representing a first mutation and a second mutation in the patient's genome; create a first instance of an abstract class of genomic feature and store in the first instance a number representing a start position in a reference human genome and at least one IUPAC character representing a nucleotide found in the patient genome at the start position and not found in the reference human genome; create a second instance of the abstract class and store in the second instance a second number representing a second start position--different from the first start position--in the reference human genome and at least one second IUPAC character representing a nucleotide found in the patient genome at the second start position and not found in the reference human genome comprising a description of the second mutation as a variant of the reference; create a third instance of the abstract class and store in the third instance; the first instance, the second instance, and a description of a relationship between the first instance and the second instance; and provide a description of the genome based on the third instance.

10. The system of claim 9, further operable to: receive data identifying a genomic region; and create a fourth instance of the abstract class, the fourth instance comprising a description of a relationship between the genomic region and the first mutation and the second mutation.

11. The system of claim 10, wherein the genomic region is identified as one selected from the list consisting of: exon, intron, gene, and ORF.

12. The system of claim 10, wherein the genomic region is identified as one selected from the list consisting of: regulatory region, promoter, splice site, and non-coding region.

13. The system of claim 10, wherein the genomic region is identified as one selected from the list consisting of: epigenetically modified region and methylated sequence.

14. The system of claim 10, wherein the genomic region is identified as one selected from the list consisting of: protein motif and protein secondary structure.

15. The system of claim 9, wherein the first mutation is not already stored within the system.

16. The system of claim 15, further operable to store the first instance in one or more computer storage devices.

Details for Patent 9,298,804

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Good Start Genetics, Inc. (Cambridge, MA) 2032-04-09 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Good Start Genetics, Inc. (Cambridge, MA) 2032-04-09 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Good Start Genetics, Inc. (Cambridge, MA) 2032-04-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Express Scripts
McKinsey
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.